HEY2 Control of Mitochondrial Respiration in Heart Failure

Heart failure is not only a problem of impaired contractility. It is also a disorder of cardiomyocyte energy management, in which mitochondrial respiration, substrate utilization, redox balance, and cell survival become progressively disturbed. The study The transcriptional repressor HEY2 regulates mitochondrial oxidative respiration to maintain cardiac homeostasis addresses an important unresolved question: how is the transcriptional activity of mitochondrial oxidative programs restrained or redirected during cardiac stress?

Published in Nature Communications, the reference study proposes that HEY2 is a central regulator of this process. The investigators show that HEY2 is increased in hearts from patients with dilated cardiomyopathy and that experimentally elevated Hey2 impairs mitochondrial respiration in zebrafish hearts and mammalian cardiomyocytes. Conversely, Hey2 depletion activates mitochondrial oxidation genes, improves cardiac function, and protects adult mouse hearts from doxorubicin-induced dysfunction.

Study Background and Research Question

Adult cardiomyocytes rely heavily on fatty acid oxidation to generate ATP through mitochondrial oxidative phosphorylation. In heart failure, this metabolic organization is commonly disrupted, with cells shifting toward glycolysis while mitochondrial electron transport, ATP production, and redox control deteriorate. Increased reactive oxygen species and defective mitochondrial dynamics can further damage cardiomyocytes, creating a feed-forward cycle of energetic deficiency and cell death.

The PPARGC1 coactivator system, including PPARGC1A and PPARGC1B, is a major transcriptional driver of mitochondrial biogenesis and oxidative metabolism. It works with nuclear receptors and respiratory regulators such as ESRRA to control genes required for fatty acid oxidation and oxidative phosphorylation. However, the amount and duration of PPARGC1 activity must be carefully controlled: insufficient activity compromises mitochondrial function, whereas sustained excessive activity can also damage mitochondrial structure and increase oxidative stress.

HEY2 belongs to the Hairy/Enhancer-of-split-related family of transcriptional repressors. Its established roles include cardiac development, arterial specification, ventricular maturation, and regulation of cardiac progenitor expansion. The innovation of this study is to extend HEY2 biology beyond development and examine whether this repressor also serves as an adult cardiac metabolic regulator. The central research question was whether HEY2 directly suppresses mitochondrial oxidative programs and, if so, which chromatin-associated mechanism connects HEY2 to cardiac energy homeostasis.

Key Innovation from the Reference Study

The study defines an HEY2/HDAC1–Ppargc1/Esrra/Cpt regulatory module. In this model, HEY2 occupies promoters of genes that support mitochondrial metabolism and colocalizes with HDAC1, a histone deacetylase associated with transcriptional repression. This association is linked to histone deacetylation and reduced expression of metabolic genes, providing a mechanistic explanation for how a developmental transcriptional repressor can influence mitochondrial respiration in the adult heart.

This is more informative than simply associating HEY2 expression with heart failure. The experimental evidence connects HEY2 abundance to chromatin occupancy, metabolic gene expression, mitochondrial bioenergetics, reactive oxygen species, apoptosis, and cardiac performance. The investigators also use gain-of-function, loss-of-function, and rescue experiments across vertebrate and mammalian systems. That layered design strengthens the interpretation that HEY2 is not merely a marker of cardiac stress but an active regulator of a conserved metabolic program.

Methods and Experimental Design Insights

The research combines human disease relevance with mechanistic experimentation. Analysis of dilated cardiomyopathy hearts establishes the clinical association between elevated HEY2 and diseased myocardium. Zebrafish models then provide an in vivo system for testing whether induced Hey2 expression is sufficient to disrupt cardiac mitochondrial function. Complementary experiments in mammalian cardiomyocytes assess whether the same regulatory relationship is preserved in a more directly comparable cellular context.

The investigators also use depletion approaches in adult mouse hearts and zebrafish. This loss-of-function arm is essential because it tests whether reducing Hey2 can improve mitochondrial gene expression and cardiac function, rather than only showing that excessive Hey2 is harmful. Doxorubicin-induced cardiac injury provides an additional stress model in which the protective effect of Hey2 knockdown can be evaluated.

Multifaceted genome-wide analyses are used to identify HEY2-enriched genomic regions and connect them to genes involved in metabolism. Promoter-level enrichment at Ppargc1, Esrra, and Cpt1-related loci is particularly important because these genes sit upstream of mitochondrial oxidation and fatty acid utilization. Chromatin analysis showing HEY2 and HDAC1 colocalization supports a transcriptional repression mechanism rather than an indirect consequence of cell injury.

Protocol Parameters

• Clinical anchoring: begin by comparing HEY2 expression and mitochondrial metabolic signatures in dilated cardiomyopathy tissue with appropriate non-diseased cardiac controls; this is a study-derived design principle rather than a universal sample-size recommendation.
• Gain-of-function arm: induce Hey2 in zebrafish hearts and mammalian cardiomyocytes to test whether increased repressor activity is sufficient to reduce respiration and compromise cell survival.
• Loss-of-function arm: deplete Hey2 in adult mouse hearts and zebrafish, then assess mitochondrial oxidation gene expression, bioenergetics, and cardiac performance.
• Mechanistic readouts: pair mitochondrial respiration and reactive oxygen species measurements with apoptosis assays and transcriptional profiling so that metabolic changes are interpreted alongside cellular injury.
• Chromatin mechanism: use genome-wide occupancy and chromatin analyses to evaluate promoter enrichment and HEY2–HDAC1 association at mitochondrial metabolic genes.
• Rescue experiments: restore PPARGC1A or ESRRA in Hey2-overexpressing zebrafish hearts or human cardiomyocyte-like cells to determine whether downstream activation can recover mitochondrial bioenergetics.
• Stress testing: use doxorubicin-induced cardiac dysfunction as a disease-relevant challenge for evaluating whether Hey2 depletion provides functional protection.

For researchers adapting this framework, the key lesson is to avoid relying on a single endpoint. HEY2-dependent metabolic repression is best evaluated through an integrated sequence of expression, chromatin, mitochondrial, redox, apoptosis, and organ-level cardiac measurements.

Core Findings and Why They Matter

First, HEY2 is upregulated in human dilated cardiomyopathy hearts. This observation places the repressor within a clinically relevant disease context and is consistent with the idea that metabolic repression accompanies cardiac failure.

Second, induced Hey2 expression produces a coordinated pathological phenotype. Mitochondrial respiration declines, reactive oxygen species increase, cardiomyocyte apoptosis is promoted, and cardiac failure develops in the experimental models. These findings connect a transcriptional event to the bioenergetic and structural consequences of heart failure.

Third, Hey2 depletion has the opposite effect. In adult mouse hearts and zebrafish, reducing Hey2 enhances expression of genes involved in mitochondrial oxidation and improves cardiac function. The protective response to doxorubicin-induced dysfunction further suggests that HEY2 may influence the heart’s ability to tolerate metabolic or toxic stress.

Fourth, the study identifies PPARGC1A and ESRRA as functionally important downstream nodes. Restoring either factor in Hey2-overexpressing zebrafish hearts or human cardiomyocyte-like cells rescues deficits in mitochondrial bioenergetics. This rescue result is especially meaningful because it moves the work beyond correlation: it indicates that reactivating the suppressed oxidative program can counter at least part of the HEY2-associated phenotype.

Collectively, the findings support a model in which excessive HEY2 recruits or works with HDAC1 at metabolic gene promoters, represses the PPARGC1A–ESRRA oxidative network, and weakens mitochondrial energy production. The resulting increase in oxidative stress and apoptosis can contribute to loss of cardiac homeostasis. The work therefore positions transcriptional control of mitochondrial respiration as an important layer of heart failure biology.

Comparison with Existing Internal Articles

The internal article HEY2-HDAC1 Axis Controls Cardiac Mitochondrial Respiration is closely aligned with the reference study and provides a concise companion interpretation of the same regulatory axis. Its emphasis on the HEY2–HDAC1 relationship and repression of metabolic genes is consistent with the paper’s genome-wide and rescue-based evidence. The reference study, however, offers the broader experimental foundation by combining human cardiomyopathy observations with zebrafish, mammalian cell, and adult mouse models.

A separate internal article, Engineered mRNA Restores NPC1 Function in Niemann-Pick C1 Fibroblasts, addresses a different biological problem: restoring deficient protein expression through engineered transcripts. It is relevant as a methodological contrast, not as evidence about HEY2. That work focuses on transcript design and cellular protein production, whereas the reference study focuses on endogenous transcriptional repression and mitochondrial metabolism.

Why this cross-domain matters, maturity, and limitations

The comparison illustrates two distinct ways of regulating gene output. The cardiac paper changes transcriptional access to metabolic genes through HEY2 and HDAC1. Engineered-mRNA studies instead seek mRNA translation enhancement and improved protein production from an introduced transcript, often considering reduced immunogenicity in mRNA and mRNA modification for protein expression. These approaches should not be treated as interchangeable, and findings from an mRNA workflow cannot establish that HEY2 manipulation will improve cardiac metabolism.

The cross-domain connection is therefore currently conceptual and methodological. It may help researchers distinguish transcriptional, post-transcriptional, and translational control when designing experiments, but the HEY2 study itself does not test modified transcripts, translation regulation via eIF2α phosphorylation, or mRNA-based cardiac treatment. The evidence remains most mature for the HEY2–HDAC1 metabolic mechanism in the experimental cardiac models examined by the authors.

Limitations and Transferability

Several limitations should guide interpretation. Elevated HEY2 in dilated cardiomyopathy hearts demonstrates association, but human tissue analysis alone cannot establish that HEY2 initiates disease. The gain-of-function models may also produce expression levels or spatial patterns that do not precisely reproduce human heart failure. Conversely, depletion experiments demonstrate protective potential but do not define the safest degree, timing, or cell type for HEY2 inhibition.

Species and model differences are also important. Zebrafish cardiac physiology, mammalian cardiomyocytes, and adult mouse hearts provide complementary evidence, yet none fully reproduces the heterogeneity of human heart failure. Doxorubicin-induced dysfunction represents a specific form of cardiac injury and may not predict responses in ischemic, hypertensive, valvular, or metabolic cardiomyopathies.

The proposed HDAC1 mechanism is supported by promoter enrichment, colocalization, and transcriptional effects, but additional work could clarify how HEY2 recruitment is controlled under different stresses and whether other corepressors cooperate with the complex. The rescue experiments with PPARGC1A and ESRRA also show that downstream pathway restoration can improve bioenergetics, not that every consequence of HEY2 elevation is mediated through those factors. Future studies should therefore preserve the paper’s integrated strategy while testing disease-specific contexts and longer-term functional outcomes.

Research Support Resources

The reference paper is the primary resource for the HEY2/HDAC1–Ppargc1/Esrra/Cpt model, experimental design, and cardiac findings. For separate transcript-engineering workflows, researchers can use N1-Methylpseudouridine (SKU B8340), a modified nucleoside intended to support mRNA translation enhancement, reduced immunogenicity in mRNA, and mRNA modification for protein expression. Product information describes a relationship to translation regulation via eIF2α phosphorylation; these applications remain distinct from the HEY2 mechanism and should be evaluated with the appropriate mRNA-specific controls and handling guidance.